Sandra Re

497 total citations
6 papers, 52 citations indexed

About

Sandra Re is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Sandra Re has authored 6 papers receiving a total of 52 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 2 papers in Immunology and 1 paper in Molecular Biology. Recurrent topics in Sandra Re's work include CAR-T cell therapy research (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Immunotherapy and Immune Responses (2 papers). Sandra Re is often cited by papers focused on CAR-T cell therapy research (4 papers), Cancer Immunotherapy and Biomarkers (4 papers) and Immunotherapy and Immune Responses (2 papers). Sandra Re collaborates with scholars based in United States, France and Italy. Sandra Re's co-authors include F. Stephen Hodi, Jedd D. Wolchok, Michael A. Postow, James Larkin, Ahmad A. Tarhini, Michael B. Atkins, Wim van Dijck, Lillian Werner, Andriy Moshyk and Corey Ritchings and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Cancers.

In The Last Decade

Sandra Re

5 papers receiving 52 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Sandra Re United States	4	38	21	15	10	9	6	52
Christina Almonte United States	3	30 0.8×	31 1.5×	19 1.3×	14 1.4×	9 1.0×	3	56
Alain Gratet France	3	23 0.6×	11 0.5×	16 1.1×	9 0.9×	5 0.6×	7	43
Spartak Valev Bulgaria	3	47 1.2×	9 0.4×	20 1.3×	10 1.0×	9 1.0×	6	69
Lysanne Desharnais Canada	3	40 1.1×	21 1.0×	9 0.6×	12 1.2×	34 3.8×	6	65
Nelusha Amaladas United States	4	28 0.7×	25 1.2×	10 0.7×	8 0.8×	14 1.6×	7	48
Alexander H. Song United States	2	22 0.6×	17 0.8×	16 1.1×	13 1.3×	6 0.7×	5	44
Giovanni Valenti Germany	3	50 1.3×	23 1.1×	11 0.7×	9 0.9×	34 3.8×	3	79
Syed Muhammad Fahmy Alkaff Singapore	2	29 0.8×	17 0.8×	6 0.4×	16 1.6×	9 1.0×	2	42
Richard Packer United Kingdom	5	25 0.7×	24 1.1×	21 1.4×	16 1.6×	16 1.8×	9	76
Julie S. Deutsch United States	5	26 0.7×	12 0.6×	21 1.4×	4 0.4×	8 0.9×	9	43

Countries citing papers authored by Sandra Re

Since Specialization

Citations

This map shows the geographic impact of Sandra Re's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sandra Re with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sandra Re more than expected).

Fields of papers citing papers by Sandra Re

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sandra Re. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sandra Re. The network helps show where Sandra Re may publish in the future.

Co-authorship network of co-authors of Sandra Re

This figure shows the co-authorship network connecting the top 25 collaborators of Sandra Re. A scholar is included among the top collaborators of Sandra Re based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sandra Re. Sandra Re is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

6 of 6 papers shown

1.

Hasegawa, Kosei, J-Y. Lee, Yuting Gao, et al.. (2025). LBA42 Raludotatug deruxtecan (R-DXd) in patients (pts) with platinum-resistant ovarian cancer (PROC): Primary analysis of the phase II dose-optimization part of REJOICE-Ovarian01. Annals of Oncology. 36. S1585–S1586.

2.

Ray-Coquard, Isabelle Laure, Debra L. Richardson, Kosei Hasegawa, et al.. (2024). REJOICE-Ovarian01: A phase 2/3 study of raludotatug deruxtecan (R-DXd) in patients with platinum-resistant ovarian cancer (OVC).. Journal of Clinical Oncology. 42(16_suppl). TPS5625–TPS5625. 6 indexed citations

3.

Homicskó, Krisztián, Reinhard Dummer, Christoph Höeller, et al.. (2022). Proton Pump Inhibitor Use and Efficacy of Nivolumab and Ipilimumab in Advanced Melanoma. Cancers. 14(9). 2300–2300. 11 indexed citations

4.

Regan, Meredith M., Charlene Mantia, Lillian Werner, et al.. (2021). Treatment-free survival over extended follow-up of patients with advanced melanoma treated with immune checkpoint inhibitors in CheckMate 067. Journal for ImmunoTherapy of Cancer. 9(11). e003743–e003743. 26 indexed citations

5.

Robert, Caroline, Georgina V. Long, James Larkin, et al.. (2020). 1082MO 5-year characterization of complete responses in patients with advanced melanoma who received nivolumab plus ipilimumab (NIVO+IPI) or NIVO alone. Annals of Oncology. 31. S734–S735. 7 indexed citations

6.

Atkins, Michael B., John M. Kirkwood, Jedd D. Wolchok, et al.. (2019). Long-term follow-up of CA209-004: A phase I dose-escalation study of combined nivolumab (NIVO) and ipilimumab (IPI) in patients with advanced melanoma.. Journal of Clinical Oncology. 37(15_suppl). 9533–9533. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact